Shengjing Hospital of China medical university

Shengyang, Liaoning 110022

1 studies enrolling now · 3 studies all time

What they study most

Acute Myelogenous Leukemia, Advanced Solid Tumors, Myelodysplastic Syndromes (MDS), Relapsing Remitting Multiple Sclerosis

Studies at this site

• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — Recruiting now
• A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors — Completed
• A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis — Status unconfirmed